In vitro activity of moxifloxacin against Stenottophomonas maltophilia blood isolates from patients with hematologic malignancies

Venditti, Mario; Monaco, Monica; Micozzi, Alessandra; Tarasi, A.; Friedrich, A; Martino, Pietro

doi:10.1046/j.1469-0691.2001.00191.x

Cited by 10 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternative agents, such as blactams (ticarcillin-clavulanate and ceftazidime), fluoroquinolones (ciprofloxacin), minocycline, and chloramphenecol, have been used with variable success and most often in combination regimens. The newer fluoroquinolones, such as moxifloxacin, appear to be more active than older agents, such as ciprofloxacin, because they inhibit many ciprofloxacin-resistant strains [71]. This differential activity might be clinically important, because nearly one-half of S. maltophilia blood culture isolates from neutropenic patients [72], and a substantial proportion of isolates obtained from lower respiratory samples are resistant to ciprofloxacin [73].…”

Section: Treatment Considerationsmentioning

confidence: 99%

Stenotrophomonas maltophilia: Changing Spectrum of a Serious Bacterial Pathogen in Patients with Cancer

Safdar

Rolston²

2007

Clinical Infectious Diseases

204

125

View full text Add to dashboard Cite

Stenotrophomonas maltophilia colonization/infection in patients with cancer has significantly increased over the past 2 decades. Patients with prolonged neutropenia, exposure to broad-spectrum antibiotics, and those requiring mechanical ventilation have higher risk of infection. These micro-organisms are intrinsically resistant to carbapenems, and exposure to these agents has been linked to selection of S. maltophilia. Recently, these infections are being documented in patients without traditional risk factors. The spectrum of infection includes bacteremia, catheter-related infection, pneumonia, complicated biliary and urinary tract infection, and skin and skin-structure infection. Trimethoprim-sulfamethoxazole is the therapeutic agent of choice, but resistance is increasingly being reported. Susceptibility to alternative agents is unpredictable. Combination therapy and alternative routes of drug administration, such as aerosolized aminoglycoside, might be necessary. New insights into the mechanisms of drug resistance might lead to identification of new target sites. Agents that improve outer-membrane permeability and broad-spectrum beta-lactamase inhibitors may favorably impact difficult-to-treat (i.e., multidrug resistant) S. maltophilia infections.

show abstract

Section: Treatment Considerationsmentioning

confidence: 99%

Stenotrophomonas maltophilia: Changing Spectrum of a Serious Bacterial Pathogen in Patients with Cancer

Safdar

Rolston²

2007

Clinical Infectious Diseases

204

125

View full text Add to dashboard Cite

show abstract

“…Alternatively, in cases of TMP/SXT-resistant infections, ticarcillin/clavulanate, ceftazidime, ciprofloxacin and levofloxacin can be used [71].…”

Section: Stenotrophomas Maltophiliamentioning

confidence: 99%

Prophylaxis and treatment options for bacterial and fungal infections in recipients of hematopoietic stem cell transplantation: Brief review

Niyazi¹

2023

GSC Biol. Pharm. Sci.

View full text Add to dashboard Cite

Patients after hematopoietic stem cell transplantation are a risk group for developing various complications. Most of them are caused by infectious agents. Important in the post-transplant period is the prevention and therapy of these infectious complications, which often lead to high morbidity and mortality rates. The aim of this review is to present briefly the options for prevention and therapy of bacterial and mycotic infectious complications in these patients following hematopoietic stem cell transplantation.

show abstract

“…One class of antibiotics that has received increased attention for its potential usage in the treatment of S. maltophilia infections is fluoroquinolones . Of the quinolones studied, moxifloxacin seems to be one of the most potent . Moxifloxacin is a third‐generation quinolone, active both against gram‐positive and gram‐negative microorganisms and also against anaerobic bacteria .…”

mentioning

confidence: 99%

“…Many studies to test the susceptibility of S. maltophilia to various anti-microbial agents have been performed (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15). One class of antibiotics that has received increased attention for its potential usage in the treatment of S. maltophilia infections is fluoroquinolones (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15). Of the quinolones studied, moxifloxacin seems to be one of the most potent (4)(5)(6)(7)(8)(9)(10)(11)(12).…”

mentioning

confidence: 99%

“…Moxifloxacin is a third-generation quinolone, active both against gram-positive and gram-negative microorganisms and also against anaerobic bacteria (16,17). The susceptibility rates of S. maltophilia to moxifloxacin vary between 80% and 96.4% (4)(5)(6)(7)(8)(9)(10)(11)(12). Another study showed activity of moxifloxacin against isolates resistant to trimethoprimsulfamethoxazole (10).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia

Ioannidis

Papaziogas

Tsiaousis

et al. 2014

Microbiology and Immunology

View full text Add to dashboard Cite

In order to investigate the effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia, 144 white male Wistar rats were randomized into six groups: Groups A and B received saline or moxifloxacin once per day, respectively; Groups C and D received saline or moxifloxacin twice per day, respectively, and Groups E and F received saline or moxifloxacin three times per day, respectively. Blood samples were taken at 6 and 30 hr after administration of S. maltophilia. Malonodialdehyde (MDA), WBC counts, bacterial tissue overgrowth, serum concentrations of moxifloxacin and survival were assessed. Survival analysis proved that treatment with moxifloxacin every 8 hr was accompanied by longer survival than occurred in any other group. Tissue cultures 30 hr after bacterial challenge showed considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals, but not in their livers. At 6 hr there were no statistically significant differences between groups. However, at 30 hr, MDA concentrations were significantly greater (P ¼ 0.044) and WBC counts significantly lower (P ¼ 0.026) in group D than in group C. No statistically significant variations were observed between the other groups. Moxifloxacin possibly stimulates lipid peroxidation and enhances phagocytosis, as indicated by MDA production and survival prolongation, without being toxic, as indicated by WBC count. Therefore, under the appropriate conditions, moxifloxacin has a place in treatment of infections in immunosuppressed patients and of infections caused by S. maltophilia. Key words immunosuppression, malonodialdehyde, moxifloxacin.The number of immunosuppressed patients is constantly increasing as a result of increased frequency of organ transplantation, increased use of chemotherapy to treat malignancies and of immunomodulative drugs to treat autoimmune diseases and increased incidence of diseases that cause immunodeficiency. Infections in these patients pose significant clinical problems regarding both diagnosis and treatment.Soft tissue infections, which may be nosocomial or community infections, present with higher frequency List of Abbreviations: ER, endoplasmic reticulum; JNK, c-Jun N-terminal kinases; MAP, mitogen-activated protein; MDA, malonodialdehyde; NFkB, nuclear factor kappa-light-chain-enhancer of activated B cells; ROS, reactive oxygen species; THP-1, human acute monocytic leukemia cell line.

show abstract

In vitro activity of moxifloxacin against Stenottophomonas maltophilia blood isolates from patients with hematologic malignancies

Cited by 10 publications

References 20 publications

Stenotrophomonas maltophilia: Changing Spectrum of a Serious Bacterial Pathogen in Patients with Cancer

Stenotrophomonas maltophilia: Changing Spectrum of a Serious Bacterial Pathogen in Patients with Cancer

Prophylaxis and treatment options for bacterial and fungal infections in recipients of hematopoietic stem cell transplantation: Brief review

Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia

Contact Info

Product

Resources

About